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OBJECTIVE— The purpose of this study was to compare quality of life (QoL) and treatment
satisfaction using insulin glargine plus insulin lispro with that using NPH insulin plus unmod-
ified human insulin in adults with type 1 diabetes managed with multiple injection regimens.
RESEARCH DESIGN AND METHODS— As part of a 32-week, five-center, two-way
crossover study in 56 individuals with type 1 diabetes randomized to evening insulin glargine
plus mealtime insulin lispro or to NPH insulin (once or twice daily) plus mealtime unmodified
human insulin, the Diabetes Treatment Satisfaction Questionnaire (DTSQ) and the Audit of
Diabetes Dependent Quality of Life questionnaire were completed at baseline and at weeks 16
and 32, with additional interim DTSQ measurements.
RESULTS— For all patients combined, the mean baseline present QoL score was 1.3, reflect-
ing “good” QoL. Present QoL improved with glargine lispro but did not change with NPH
human insulin (1.6  0.1 [mean  SEM] vs. 1.3  0.1, difference 0.3 [95% CI 0.1–0.6]; P 
0.014). Baseline mean average weighted impact score (AWI) of diabetes on QoL was 1.8,
indicating a negative impact of diabetes on QoL. The AWI score at end point improved signifi-
cantly with glargine  lispro but changed little with NPH  human insulin (1.4  0.1 vs.
1.7 0.1, 0.3 [0.0–0.6]; P 0.033). Treatment satisfaction (DTSQ 36-0 scale score) at end
point was markedly greater with glargine plus lispro compared with that for NPH plus human
insulin (32.2  3.4 vs. 23.9  7.2, 8.6 [6.5–10.6]; P  0.001).
CONCLUSIONS— Insulin glargine plus insulin lispro improves treatment satisfaction, re-
duces the negative impact of diabetes on QoL, and improves QoL in comparison with NPH
insulin plus unmodified human insulin in type 1 diabetes.
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The primary aim for most physiciansadvising patients on the manage-ment of type 1 diabetes is to help the
individual to achieve good blood glucose
control without excessive hypoglycemia.
One of the management strategies that
can be used to achieve this aim is the use
of analog insulin preparations in a multi-
ple daily injection regimen. However,
many physicians are concerned that the
increased number of injections might
have a negative impact on individual
quality of life (QoL) (1), although others
have anticipated the QoL benefits that
may follow from a regimen that allows
flexible eating and insulin dosing (23).
The maintenance, or indeed improve-
ment, in psychological outcomes such as
QoL and treatment satisfaction should
thus be an additional but related goal in
the management of patients with type 1
diabetes (4). Rapid- and extended-acting
insulin analogs have been shown to im-
prove blood glucose control in individu-
als with type 1 diabetes (5–10). However,
it cannot be assumed that these therapies
concurrently improve psychological out-
comes. The evaluation of QoL and, more
specifically, treatment satisfaction is thus
an important part of the assessment of
new insulin preparations.
The combination of insulin glargine
with a rapid-acting insulin analog such as
insulin lispro provides a more physiolog-
ical replacement of mealtime and basal in-
sulin compared with previous insulin
regimens. It was previously shown, in the
same study participants as those involved
in the present report, that insulin glargine
in combination with insulin lispro im-
proves overall glycemic control, as as-
sessed by A1C and 24-h plasma glucose
monitoring, to a clinically significant
degree, together with a reduction in noc-
turnal hypoglycemia (8). Although psy-
chological outcomes have been evaluated
in studies comparing insulin glargine
with NPH insulin (4) and rapid-acting
insulin analogs with unmodified human
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insulin (11–14), there are no comprehen-
sive reports of psychological outcomes
comparing a combined rapid-acting and
long-acting analog regimen with NPH in-
sulin plus unmodified human insulin.
Here we report treatment satisfaction,
overall QoL, and the impact of diabetes
on QoL in a randomized clinical trial
comparing once-daily insulin glargine 
insulin lispro with once- or twice-daily
NPH insulin  unmodified human insu-
lin in adults with type 1 diabetes.
RESEARCH DESIGN AND
METHODS— A 32-week, open, ran-
domized, two-way cross-over clinical trial
in individuals with type 1 diabetes was
conducted in five U.K. sites. The study
was approved by local ethics committees,
and written informed consent was ob-
tained from all participants before the
study began. The study design and meta-
bolic outcome measures have been re-
ported in detail previously (8). Here we
present the psychological outcome mea-
sures recorded during the study.
Seventy-one individuals were re-
cruited (by examination of their medical
records with regard to inclusion criteria
followed by invitation to enter the study).
Two withdrew before random assign-
ment, and 13 did not fulfill study inclu-
sion criteria. Fifty-six individuals were
randomized. Two individuals withdrew
after random assignment but before re-
ceiving the study treatment(one in each
group). Neither knew the treatment they
had been randomized to receive; 54 indi-
viduals were thus randomized and
treated. Three individuals withdrew dur-
ing the study (two randomized to glargine
plus lispro, and one to NPH plus unmod-
ified human insulin, all during the first
treatment period), and 51 completed the
study. One individual withdrew because
of an adverse event, one felt unable to
continue with the demands of the study
protocol, and one was unable to complete
the 24-h in-patient studies.
A modified intention-to-treat (ITT)
sample was used for all psychological
analyses, consisting of all randomized
participants who received at least one
dose of the study medication and had at
least one postbaseline efficacy measure-
ment of treatment satisfaction or QoL in
each treatment period. This sample con-
sisted of 48 individuals, 22 randomized to
insulin glargine plus insulin lispro for the
first treatment period and 26 to NPH in-
sulin plus unmodified human insulin (Ta-
ble 1). Insufficient questionnaire data
were collected for the remaining 3 partic-
ipants to allow inclusion. There were no
clinically significant differences between
the recorded characteristics of the modi-
fied ITT sample for the QoL analysis and
those of the main efficacy study sample.
The modified ITT sample for the QoL
analysis consisted of 18 men and 30
women, aged 18–65 years with type 1
diabetes and no previous experience of
insulin glargine, who had been using a
multiple insulin injection regimen for at
least 1 year (mean SD 10.5 8.4 years)
before randomization. Participants had a
random C-peptide level of 0.10 nmol/l
and A1C of 7.0 –9.5% (nondiabetic
5.9%). Two of the study centers and
thus some of the participants recruited at
these sites had previously taken part in
the Dose Adjustment For Normal Eating
(DAFNE) study and had thus been
trained in insulin dose adjustment to al-
low considerable dietary freedom. It has
been shown that DAFNE training resulted
in significant improvements in treatment
satisfaction using the Diabetes Treatment
Satisfaction Questionnaire (DTSQ) and
both present QoL and the impact of dia-
betes on QoL measured by the Audit of
Diabetes Dependent Quality of Life (AD-
DQoL) (15). There were no statistically
significant differences in baseline charac-
teristics between the two randomized
groups.
After a 4-week screening period dur-
ing which previous insulin therapy was
continued, individuals were randomized
to bedtime insulin glargine (Lantus;
sanofi-aventis, Paris, France) in combina-
tion with premeal insulin lispro (Huma-
log; Eli Lilly, Indianapolis, IN) (glargine
 lispro) or to NPH insulin (HOE
36HPR; sanofi-aventis) in combination
with premeal unmodified human insulin
(HOE 31HPR; sanofi-aventis) (NPH 
human). Randomizing was by telephone
using a central computer randomization
program.
The first 4 weeks of the 16-week
treatment period consisted of a dose titra-
tion period during which study visits oc-
curred weekly. In the subsequent 12
Table 1—Characteristics of the modified, randomized, and treated ITT sample with type 1
diabetes
Glargine  lispro in
first treatment
period
NPH  human in
first treatment period
n 22 26
Sex (male/female) 7/15 11/15
Age (years) 41.7  13.9 42.2  9.1
BMI (kg/m2) 26.3  2.8 25.8  3.0
Weight (kg) 72.9  11.1 73.5  9.6
Duration of diabetes (years) 22.3  15.5 21.5  10.7
A1C 8.1  0.8 8.0  0.8
Prestudy insulin therapy
Basal insulin
Once-daily NPH insulin 12 (55) 17 (65)
Twice-daily NPH insulin 5 (23) 6 (23)
Insulin zinc suspension 3 (14) 2 (8)
Unknown/other 2 (9) 1 (4)
Meal-time insulin
Unmodified human insulin 14 (64) 16 (62)
Rapid-acting insulin analog 8 (36) 9 (35)
Unknown 0 1 (4)
ADDQoL scores
Present Qol 1.4  0.8 1.2  1.3
Diabetes-specific QoL 1.7  1.1 1.8  1.0
Average weighted impact of diabetes on QoL 0.7  0.5 0.9  0.5
DTSQ scores
Treatment satisfaction 29.4  5.0 28.2  6.3
Perceived frequency of hyperglycemia 3.9  1.0 3.6  1.4
Perceived frequency of hypoglycemia 2.9  1.5 2.3  1.2
Data are means  SD or n (%). All randomized participants who received at least one dose of the study
medication and had at least one postbaseline efficacy measurement of treatment satisfaction or QoL in each
treatment period are included. There were no statistically significant differences between groups.
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weeks, visits were fortnightly or more fre-
quently if necessary. At each consultation
self-monitored blood glucose levels and
insulin doses were reviewed, and insulin
doses were titrated according to a target-
driven algorithm that was identical for all
study sites and both insulin regimens.
Target blood glucose levels were identical
for each regimen: preprandial and post-
prandial targets were 4.0–6.5 mmol/l in
the absence of hypoglycemia. The blood
glucose target for 0300 h was 5.0
mmol/l.
Insulin glargine was initially given at
bedtime but could be injected earlier in
the evening if blood glucose levels were
frequently high or rising at bedtime or
0300 h. All individuals randomized to the
human insulin regimen received NPH in-
sulin once daily at bedtime or twice daily
at bedtime and breakfast, the frequency of
injection being determined by the indi-
vidual’s prior dosing frequency. Insulin
lispro was recommended to be given im-
mediately before meals, whereas partici-
pants were recommended to inject
unmodified human insulin 30 min before
eating. The OptiPen Pro-1 injection de-
vice (sanofi-aventis) was used to give all
insulin injections except insulin lispro
(HumaPen Ergo; Eli Lilly).
At the end of the 16-week treatment
period, participants were admitted for a
24-h in-patient plasma glucose assess-
ment. At the end of the first 24-h study,
participants began the alternative insu-
lin regimen, and the study sequence was
repeated.
Questionnaires
The DTSQ andADDQoL questionnaire
are self-administered instruments that
have demonstrated validity and reliability
in diabetes patient populations (4,14,16–
19).
Treatment satisfaction was assessed
using the DTSQ (18,19). This is an eight-
item questionnaire in which each item is
scored on a 7-point scale. The treatment
satisfaction score is the sum of six of the
items of the DTSQ for each respondent. The
additional two items measure perceived fre-
quency of hyperglycemia and hypoglyce-
mia and are considered separately.
The DTSQ status version (DTSQs) as-
sesses treatment satisfaction over the few
weeks before its completion. Each item is
scored from 6 to 0 with a higher score
indicating greater satisfaction. The treat-
ment satisfaction score can thus range
from 36 (very satisfied) to 0 (very dissat-
isfied). The two additional items measur-
ing perceived frequency of hypo- and
hyperglycemia are scored from 0 (none of
the time) to 6 (most of the time). The
DTSQs can be limited by a ceiling effect
when treatment satisfaction is high at
baseline (20). The DTSQ change version
(DTSQc) uses the same eight-item stems
as the DTSQs but has different response
options and asks respondents to assess
changes in treatment satisfaction with
their current treatment compared with
their previous treatment and thus over-
comes any ceiling effect that may occur
with the DTSQs (14). Each of the six
items of the DTSQc is scored from 3
(e.g., much more satisfied now) to 3
(e.g., much less satisfied now). The
DTSQc treatment satisfaction change
score can thus range from 18 to 18.
The items measuring perceived frequency
of hypo- and hyperglycemia were scored
from 3 (much less of the time now) to
3 (much more of the time now) such
that a higher score indicates more hyper-
or hypoglycemia.
The DTSQs was completed at base-
line and at weeks 8 and 16 of each 16-
week treatment period. The DTSQc was
completed once at the end of the study.
The impact of diabetes on QoL was
assessed using the ADDQoL question-
naire. Eighteen of the 20 items of the
ADDQoL concern specific life domains
such as social life and working life and are
scored on a 7-point impact scale, accom-
panied by a related importance rating
scale for each domain used to assess the
importance of each aspect of life for the
individual’s QoL. The impact of diabetes
on each of these life domains is then
weighted by the domain’s importance for
the respondent’s QoL and the resulting
weighted impact scores are averaged
across all applicable domains to provide
an average weighted impact (AWI) score.
Weighted impact scores for single do-
mains and the AWI score can range from
9 (maximum positive impact of diabe-
tes) to 9 (maximum negative impact of
diabetes). The two remaining overview
items are scored separately and include a
single diabetes-specific QoL item measur-
ing the impact of diabetes on QoL that is
scored from 3 (maximum positive im-
pact of diabetes) to 3 (maximum nega-
tive impact of diabetes) and a single item,
present QoL, that is scored from 3 (ex-
cellent) to3 (extremely bad) to measure
overall QoL. The ADDQoL was com-
pleted at baseline and at the end point of
each treatment period (weeks 16 and 32).
To achieve a high response rate, par-
ticipants were asked to complete the
questionnaires during trial visits and to
return them to the investigators in a
sealed envelope. The completed ques-
tionnaires were not inspected by the in-
vestigators but were analyzed by a
statistician blinded to the randomized
group.
Statistical analysis
Sample size was calculated using A1C, the
primary end point of the main study (8).
Participant-reported outcomes from the
ADDQoL and DTSQ were analyzed by an
ANOVA model including period and se-
quence effects. All statistical tests were
performed at a two-sided significance
level of   5%. Data provided are
means SEM and mean difference (95%
CI) unless otherwise stated. Analysis was
performed using SAS software (SAS Insti-
tute, Cary, NC). The model included
fixed effects for treatment, sequence, and
period, as well as a random effect to ac-
count for subjects within sequence.
RESULTS
ADDQoL
The mean SD present QoL score for the
whole study sample at baseline was 1.3
1.1, reflecting “good” rather than “very
good” or “excellent” QoL. The AWI
score  SD at baseline was 1.8  1.2,
indicating an overall negative impact of
diabetes on QoL.
The present QoL score increased by
0.3 points during treatment with glargine
 lispro but did not change with NPH
human (end point scores 1.6  0.1
[mean  SEM) vs. 1.3  0.1, difference
0.3 [95% CI 0.1–0.6]; P  0.014) (Fig.
1A). Diabetes-specific QoL at end point
did not differ between treatment groups
(1.4 0.1 vs.1.5 0.1, 0.2 [0.1 to
0.5], NS).
The AWI score improved by 0.4
points with glargine lispro but changed
little with NPH  human (end point
scores1.4 0.1 vs.1.7 0.1, differ-
ence 0.3 [95% CI 0.0–0.6]; P  0.033).
The AWI score followed a pattern during
the study similar to that of present QoL
(Fig. 1A). The negative impact of diabetes
on QoL in the following domains was im-
proved with glargine  lispro compared
with NPH  human: social life (0.8 
0.2 vs. 1.8  0.2, 1.0 [0.3–1.7]; P 
0.007), sex life (0.8  0.2 vs. 1.5 
0.2, 0.6 [0.1–1.2]; P  0.023), society’s
reaction (0.7 0.1 vs.1.1 0.1, 0.4
[0.0–0.7]; P 0.048), and enjoyment of
QoL with insulin analogs
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food [1.6  0.1 vs. 2.1  0.1, 0.5
[0.1– 0.9]; P  0.014).
DTSQ
Treatment satisfaction at baseline was
high in this population, with a mean
DTSQ treatment satisfaction score of
28.8 5.7. Nineteen individuals (39.6%)
had a baseline DTSQ summary score be-
tween 31 and the maximum of 36.
Treatment satisfaction increased by
3.2 points with glargine lispro, but de-
creased by 4.9 points with NPH  hu-
man: 32.3 0.7 vs. 23.7 0.7 (8.6 [6.5–
10.6]; P  0.001). The treatment
satisfaction score showed a progressive
increase from baseline to end point dur-
ing treatment with glargine  lispro.
Conversely, with NPH  human, there
was a progressive decrease in treatment
satisfaction through the course of the
treatment period (Fig. 1B).
Significant differences favoring
glargine  lispro were found for five of
the six items of the treatment satisfaction
scale: current satisfaction with treatment
(5.4  0.2 vs. 3.8  0.2; P  0.001),
convenience of treatment (5.3  0.1 vs.
4.1 0.1; P 0.001), flexibility of treat-
ment (5.2  0.1 vs. 3.9  0.2; P 
0.001), recommend to others (5.5  0.2
vs. 3.7 0.2; P 0.001), and satisfaction
to continue current treatment (5.7  0.2
vs. 3.2  0.2; P  0.001).
Results from the DTSQc were similar
to those obtained with the DTSQs: pre-
dominantly negative scores for items 1
and 4–8 with NPH  human indicated
worsened treatment satisfaction com-
pared with previous treatment with
glargine  lispro (Table 2 of the online
appendix available at http://dx.doi.org/
10.2337/dc07-1183).
Perceptions of blood glucose control
Perceived frequency of hyperglycemia at
end point (DTSQs) was lower with
glargine  lispro compared with NPH 
human (2.7  0.2 vs. 4.0  0.2; P 
0.001). The DTSQc showed a decrease in
perceived frequency of hyperglycemia
with insulin glargine  lispro and an in-
crease with NPH  human at end point
when respondents compared their expe-
rience of treatment in period 2 with that
in period 1 (0.8  0.5 vs. 0.5  0.5;
P 0.043) (Table 2 of the online appen-
dix).
Perceived frequency of hypoglycemia
at end point (DTSQs and DTSQc) did not
differ between glargine lispro and NPH
 human (Table 2 of the online
appendix).
CONCLUSIONS— In this study we
compared treatment satisfaction and QoL
in individuals with type 1 diabetes ran-
domized to insulin glargine plus insulin
lispro or to NPH insulin plus unmodified
human insulin, using a 32-week, open,
multicenter, two-way crossover design.
Together with observed improvements in
blood glucose control with insulin
glargine plus insulin lispro (8), QoL and
treatment satisfaction also improved
compared with NPH insulin plus unmod-
ified human insulin. Present QoL in-
creased with the analog compared with
the human insulin regimen, and the neg-
ative impact of diabetes on QoL, particu-
larly on social life, sex life, society’s
reaction, and enjoyment of food, was re-
duced. Treatment satisfaction improved
progressively through the study with in-
sulin glargine plus insulin lispro, with no-
table improvements in flexibility and
convenience.
Participants using glargine plus lispro
reported a significantly reduced percep-
tion of the frequency of hyperglycemia,
but there was no difference between treat-
ment groups in perceived frequency of
hypoglycemia on the DTSQs. However,
self-monitored and in-patient–assessed
hyperglycemia as well as symptomatic
nocturnal hypoglycemia were reduced
Figure 1—ADDQoL present QoL score (A) and DTSQs treatment satisfaction score (B) in those
who used glargine lispro (——) and in those who used NPH human (– – –) in period one of
the study, switching to the alternative insulin regimen in period 2.
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with the analog compared with the hu-
man insulin regimen (8). Episodes of all
recalled/diary-monitored symptomatic
hypoglycemia did not differ between
treatment groups. The DTSQ does not as-
sess severity of hypoglycemia. It is thus
possible that, when completing the
DTSQ, respondents would be influenced
more by frequent minor symptoms of
daytime hypoglycemia than by less fre-
quent but more troublesome instances of
more severe (e.g., nocturnal) hypoglyce-
mia to the extent that participants did not
indicate any difference in overall hypogly-
cemia between treatments.
The study was not blinded because of
differences in the appearance of the basal
insulin preparations. It is thus possible
that some of the observed improvements
in treatment satisfaction and QoL might
have simply reflected participant expecta-
tions of a new insulin regimen. Although
this possibility cannot be entirely dis-
counted, the improvements in treatment
satisfaction with insulin glargine plus
insulin lispro increased progressively
throughout the study. This result indi-
cates that any expectations of the per-
ceived benefits of the analog insulin
regimen held by participants are likely to
have been met and that such benefits were
not transient but maintained and indeed
improved further through the course of
the study. Although it would have been
technically possible, although difficult, to
blind the study, it was felt that this would
not have been acceptable to participants.
In addition, blinded study designs have
major limitations in studying psycholog-
ical outcomes relating to insulin therapy.
For example, convenience and flexibility
were improved with the analog insulin
regimen, reflecting differences between
analog and human insulin regimens in the
frequency of insulin injections and their
timing in relation to meals. A blinded de-
sign would have been unable to detect
such differences in treatment satisfaction
between regimens as such a design would
require the necessity for placebo injec-
tions, which create an artificial experience
of treatment that is more demanding than
either treatment in clinical reality.
Three of the 51 patients randomized
to the main study did not complete any
QoL or treatment satisfaction question-
naires. Although there were no clinically
significant differences between the re-
corded characteristics of this sample of 48
used for the QoL and treatment satisfac-
tion analysis and the sample of 51 used for
the main efficacy study sample, subtle dif-
ferences cannot be excluded. As in all
such studies, ascertainment bias as a re-
sult of the recruitment of patients moti-
vated to enter this clinical trial also cannot
be excluded.
Rapid-acting insulin analogs have
been shown to improve treatment satis-
faction compared with unmodified hu-
man insulin in individuals with type 1
diabetes, with reported between-group
differences in the DTSQs treatment satis-
faction score of 1.6–2.3 (11–14). Similar
studies have reported improvements in
the DTSQs treatment satisfaction score
with insulin glargine compared with NPH
insulin of 0.9–1.8 (4,21). In the current
study, however, the between-group dif-
ference in the DTSQs treatment satisfac-
tion score was much greater, at 8.6. The
between-group differences in each of the
items of the DTSQs in the current study
were also much greater than those re-
ported in previous studies comparing in-
sulin glargine with NPH insulin or rapid-
acting insulin analogs with unmodified
human insulin (4,13,22). This result sug-
gests that the combination of insulin
glargine and a rapid-acting insulin analog
might have a synergistic benefit on treat-
ment satisfaction. However, the use of
carbohydrate-counting skills and pran-
dial insulin dose adjustment by some of
the participants of the present study
might have contributed to these im-
proved QoL results.
The DAFNE study provided individ-
uals with type 1 diabetes with an educa-
tional package, at the heart of which was
the acquisition of skills to count carbohy-
drate and adjust rapid-acting insulin
doses accordingly, thus allowing dietary
flexibility (15). The improvements in
measures of QoL in individuals who un-
dertook this course compared with the
control group who were yet to do so are
similar to those recorded in the present
study comparing analog and human insu-
lin regimens: DTSQs treatment satisfac-
tion score improved by 8.8 and perceived
frequency of hyperglycemia by 1.1 in the
DAFNE study. The AWI score improved
by 0.4 and present QoL by 0.3. The only
difference between DAFNE and the
present study is the improvement in the
item “freedom to eat as I wish” that was
much greater in DAFNE. Two of the five
centers involved in the present study (that
together contributed 39% of the total
study sample) had previously taken part
in the DAFNE study. Some of the investi-
gators and participants enrolled in the
present study at these sites had thus un-
dergone DAFNE training. Although car-
bohydrate-counting and rapid-acting
dose adjustment skills were not an inclu-
sion criterion of the present study and
were not taught during the study, a high
proportion of participants recruited from
these two study sites would be likely to
have previously acquired these skills.
Some of the improved QoL and treatment
satisfaction benefits observed in the
present study (which were markedly
greater that those seen in previous studies
comparing insulin glargine with NPH in-
sulin or rapid-acting insulin analogs with
unmodified human insulin) might thus
relate to the combined benefits of an in-
sulin analog regimen and dietary freedom
in the participants who were DAFNE
trained. A post hoc analysis comparing
QoL and treatment satisfaction in DAFNE
compared with non-DAFNE centers is
problematic owing to the small number of
centers (two versus three), but ADDQoL
AWI score, freedom to eat, and present
QoL did not differ between sites (data not
shown).
It may be noted that individuals in the
present study tended to show worsened
satisfaction with the conventional insulin
regimen during the study. This is most
marked after exposure to the combined
analog regimen (Fig. 1B) and reflects the
commonly observed disappointment
with the previously satisfactory control
treatment after experiencing a treatment
that participants preferred (23).
In summary, insulin glargine in com-
bination with a rapid-acting insulin ana-
log improves both biomedical and
psychosocial outcomes compared with
NPH insulin plus unmodified human in-
sulin. These data reinforce the suggestion
that the use of combined insulin analog
therapy should be considered as an
option for all individuals with type 1
diabetes.
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